惊鸿
(2022-09-27 09:09):
#paper doi:Volume 40, Issue 9, 12 September 2022, Pages 999-1009.e6Detection and localization of early- and late-stage cancers using platelet 这篇论文解释了RNA癌症患者受益于早期肿瘤检测，因为治疗结果对不太晚期的癌症更有利。血小板参与癌症进展，被认为是癌症检测的有前途的生物来源，因为它们根据局部和全身线索改变其RNA含量。我们表明，基于肿瘤的血小板（TEP）RNA血液测试能够检测18种癌症类型。血栓形成Seq在无症状对照组的特异性为99%，在I-IV期癌症患者的1，096份血液样本中有三分之二和352名I-III期肿瘤中的一半中正确检测到癌症的存在。对症对照组，包括炎症和心血管疾病以及良性肿瘤，假阳性检测结果增加，平均特异性为78%。此外，血栓形成Seq在超过80%的癌症患者中正确确定了五种不同肿瘤类型的肿瘤起源部位。这些结果突出了TEP衍生的RNA组合的潜在特性，以补充当前基于血液的癌症筛查方法。
Detection and localization of early- and late-stage cancers using platelet RNA
翻译
Abstract:
Cancer patients benefit from early tumor detection since treatment outcomes are more favorable for less advanced cancers. Platelets are involved in cancer progression and are considered a promising biosource for cancer detection, as they alter their RNA content upon local and systemic cues. We show that tumor-educated platelet (TEP) RNA-based blood tests enable the detection of 18 cancer types. With 99% specificity in asymptomatic controls, thromboSeq correctly detected the presence of cancer in two-thirds of 1,096 blood samples from stage I-IV cancer patients and in half of 352 stage I-III tumors. Symptomatic controls, including inflammatory and cardiovascular diseases, and benign tumors had increased false-positive test results with an average specificity of 78%. Moreover, thromboSeq determined the tumor site of origin in five different tumor types correctly in over 80% of the cancer patients. These results highlight the potential properties of TEP-derived RNA panels to supplement current approaches for blood-based cancer screening.
翻译
Keywords: